Abstract

Most newly synthesized soluble lysosomal proteins contain mannose 6-phosphate (Man-6-P), a specific carbohydrate modification that is recognized by Man-6-P receptors (MPRs) that direct targeting to the lysosome. A number of proteomic studies have focused on lysosomal proteins, exploiting the fact that Man-6-P-containing forms can be purified by affinity chromatography on immobilized MPRs. These studies have identified many known lysosomal proteins as well as many proteins not previously classified as lysosomal. The latter are of considerable biological interest with potential implications for lysosomal function and as candidates for lysosomal storage diseases of unknown etiology. However, a significant problem in interpreting the biological relevance of such proteins has been in distinguishing true Man-6-P glycoproteins from simple contaminants and from proteins associated with true Man-6-P glycoproteins (e.g. protease inhibitors and lectins). In this report, we describe a mass spectrometric approach to the verification of Man-6-phosphorylation based upon LC-MS of MPR-purified proteolytic glycopeptides. This provided a useful tool in validating novel MPR-purified proteins as true Man-6-P glycoproteins and also allowed identification of low abundance components not observed in the analysis of the total Man-6-P glycoprotein mixture. In addition, this approach allowed the global mapping of 99 Man-6-phosphorylation sites from 44 known lysosomal proteins purified from mouse and human brain. This information is likely to provide useful insights into protein determinants for this modification and may be of significant value in protein engineering approaches designed to optimize protein delivery to the lysosome in therapeutic applications such as gene and enzyme replacement therapies.

Highlights

  • Most newly synthesized soluble lysosomal proteins contain mannose 6-phosphate (Man-6-P), a specific carbohydrate modification that is recognized by Man-6-P receptors (MPRs) that direct targeting to the lysosome

  • 1 The abbreviations used are: Man-6-P, mannose 6-phosphate; Man, mannose; MPR, Man-6-P receptor; sCI-MPR, soluble cationindependent MPR; Endo H, endoglycosidase H; PNGase F, peptideN-glycosidase F; Nϩ203, 203-Da increment resulting from N-acetylhexosamine linked to asparagine after oligosaccharide cleavage using Endo H; Nϩ1, 1-Da increment resulting from conversion of asparagine to aspartic acid after oligosaccharide removal using PNGase F; GM2, GalNAc␤134Gal(342␣NeuAc) ␤134Glc␤131Cer; ER, endoplasmic reticulum; AOAH, acyloxyacyl hydrolase; BTD, biotinidase; CALU, calumenin; Cat Eye Syndrome Critical Region 1 (CECR1), cat eye syndrome critical region 1; Cellular Repressor of E1A-stimulated Gene Expression (CREG), cellular repressor of E1A-stimulated gene expression; POFUT, protein O-fucosyltransferase; EPDR1, ependymin-related protein; Myelin-associated Glycoprotein (MAG), myelin-associated glycoprotein; Ribonuclease T2 (RNASET2), ribonuclease T2; SPARC-like Protein 1 (SPARCL1), SPARC-like protein 1; SUMF, sulfatasemodifying factor precursor

  • In our previous study of proteins purified from human brain by MPR affinity chromatography, we analyzed a tryptic digest of the total mixture

Read more

Summary

The abbreviations used are

Man-6-P, mannose 6-phosphate; Man, mannose; MPR, Man-6-P receptor; sCI-MPR, soluble cationindependent MPR; Endo H, endoglycosidase H; PNGase F, peptideN-glycosidase F; Nϩ203, 203-Da increment resulting from N-acetylhexosamine linked to asparagine after oligosaccharide cleavage using Endo H; Nϩ1, 1-Da increment resulting from conversion of asparagine to aspartic acid after oligosaccharide removal using PNGase F; GM2, GalNAc␤134Gal(342␣NeuAc) ␤134Glc␤131Cer; ER, endoplasmic reticulum; AOAH, acyloxyacyl hydrolase; BTD, biotinidase; CALU, calumenin; CECR1, cat eye syndrome critical region 1; CREG, cellular repressor of E1A-stimulated gene expression; POFUT, protein O-fucosyltransferase; EPDR1, ependymin-related protein (up-regulated in colon cancer I); MAG, myelin-associated glycoprotein; RNASET2, ribonuclease T2; SPARCL1, SPARC (secreted protein, acidic, and rich in cysteine)-like protein 1; SUMF, sulfatasemodifying factor precursor. Acid sphingomyelinase, a known lysosomal Man-6-P glycoprotein, is not predicted to contain a signal sequence using SignalP 3.0 [13] Such approaches are useful in eliminating some false positives, they are of limited value as many non-lysosomal proteins contain both potential N-linked glycosylation sites and predicted signal sequences [7]. A conceptual problem with this approach is that many lysosomal proteins consist of multiple subunits or chains of which some contain Man-6-P and some do not Another approach has been to express and purify candidate proteins containing His tags and demonstrate Man-6-P-dependent binding to MPRs in vitro and Man-6-P-dependent internalization and lysosomal targeting in cell lines [8], but again this is an indirect approach that cannot distinguish between true Man-6-P glycoproteins and potential contaminants that have been identified by virtue of interactions with true Man-6-P glycoproteins. We provide a database for Man-6-phosphorylation sites in known lysosomal proteins that is likely to prove valuable in terms of both the understanding of lysosomal cell biology and in bioengineering of lysosomal proteins for therapeutic applications

EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call